Alexion Pharmaceuticals Inc

Find Ratings Reports
ALXN : NASDAQ : Health Care
$118.53 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 2186600.0
03/28/17 - 4:00 PM ET

Financial Analysis


ALEXION PHARMACEUTICALS INC's gross profit margin for the fourth quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. ALEXION PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.36 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 5.27% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)830.74700.87
EBITDA ($mil)321.71224.5
EBIT ($mil)220.97130.75
Net Income ($mil)92.4466.6


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)1293.01385.02
Total Assets ($mil)13253.013133.23
Total Debt ($mil)3288.03607.56
Equity ($mil)8694.08258.62


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin94.7393.76
EBITDA Margin38.7232.03
Operating Margin26.618.65
Sales Turnover0.230.2
Return on Assets3.011.09
Return on Equity4.581.74
Debt Q4 FY16 Q4 FY15
Current Ratio3.133.38
Debt/Capital0.270.3
Interest Expense24.5123.15
Interest Coverage9.025.65


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)224.0225.65
Div / share0.00.0
EPS0.410.29
Book value / share38.8136.6
Institutional Own % n/a n/a
Avg Daily Volume2145827.02862772.0

Valuation


HOLD. ALEXION PHARMACEUTICALS INC's P/E ratio indicates a significant premium compared to an average of 38.87 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 26.33. To use another comparison, its price-to-book ratio of 3.10 indicates valuation on par with the S&P 500 average of 2.93 and a significant discount versus the industry average of 11.85. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ALXN 67.94 Peers 38.87   ALXN 24.81 Peers 22.28

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

ALXN is trading at a significant premium to its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ALXN is trading at a premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ALXN 18.14 Peers 58.77   ALXN 0.35 Peers 0.49

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

ALXN is trading at a significant discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

ALXN trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ALXN 3.10 Peers 11.85   ALXN 132.89 Peers 165.61

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ALXN is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, ALXN is expected to trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ALXN 8.73 Peers 256.31   ALXN 18.43 Peers 609.16

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ALXN is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ALXN significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades